Appeal No. 1997-2510
Application No. 07/868,539
Sakata et al. (Sakata), ”Studies on the structure and stabilizing factor of the
CUUCGG hairpin RNA using chemically synthesized oligonucleotides,” Nucleic
Acids Research, Vol. 18, No. 13, pp. 3831-3839 (1990)
Mitsuya et al. (Mitsuya), ”Molecular Targets for AIDS Therapy,” Science, Vol.
249, pp.1533-1544 (1990)
Bielinska et al. (Bielinska), ”Regulation of Gene Expression with Double-
Stranded Phosphorothioate Oligonucleotides,” Science, Vol. 250, pp. 997-1000
(1990)
Vickers et al. (Vickers), ”Inhibition of HIV-LTR gene expression by
oligonucleotides targeted to the TAR element,” Nucleic Acids Research, Vol. 19,
No. 12, pp. 3359-3368 (1991)
Everett et al. (Everett), “Purification of the DNA binding domain of herpes
simplex virus type 1 immediate-early protein Vmw175 as a homodimer and
extensive mutagenesis of its DNA recognition site,” Nucleic Acids Research, Vol.
19, No. 18, pp. 4901-4908 (1991)
Stein et al. (Stein), ”Antisense Oligonucleotides as Therapeutic Agents – Is the
Bullet Really Magical?,” Science, Vol. 261, pp. 1004-1012 (1993)
Antisense Update: Keep Your Chin Up - - Other Forms of Antisense: Lack of
Obvious Progress, Genis Report – Rx, Vol. 2, No. 4 (Genesis Group Associates,
Inc.) (1993)
Wagner, “Gene inhibition using antisense oligodeoxynucleotides,” Nature, Vol.
372, pp. 333-335 (1994)
Conference Coverage (ICAAC) Antisense Drug Stumbles in Early Trial,
Infectious Disease Weekly (Charles W Henderson) (1995)
Gura, “Antisense Has Growing Pains,” Science, Vol. 270, pp. 575-577 (1995)
Stull et al. (Stull), ”Antigene, Ribozyme and Aptamer Nucleic Acid Drugs:
Progress and Prospects,” Pharmaceutical Research, Vol. 12, No. 4, pp. 465-483
(1995)
GROUNDS OF REJECTION
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007